Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy.

IF 3.7 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Journal of Gastroenterology and Hepatology Pub Date : 2024-11-05 DOI:10.1111/jgh.16791
Yu-De Chu, Chao-Wei Hsu, Pei-Huan Ho, Chih-Yung Chiou, Chih-Lang Lin, Kung-Hao Liang, Ming-Wei Lai, Chau-Ting Yeh
{"title":"Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy.","authors":"Yu-De Chu, Chao-Wei Hsu, Pei-Huan Ho, Chih-Yung Chiou, Chih-Lang Lin, Kung-Hao Liang, Ming-Wei Lai, Chau-Ting Yeh","doi":"10.1111/jgh.16791","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatitis B virus (HBV) reactivation could develop after withdrawal following a finite course of nucleoside analog (NA) therapy, leading to virological and clinical relapses. The genetic heterogeneity in the HBV surface and polymerase genes during finite NA therapy has not been carefully studied.</p><p><strong>Methods: </strong>Seven chronic HBV-infected patients experiencing relapses following entecavir (ETV; n = 5; Patients 1 to 5) or tenofovir disoproxil fumarate (TDF; n = 2; Patients 6 and 7) withdrawal were included. Sera obtained before treatment and at relapses were retrieved and submitted for DNA extraction and amplicon-specific deep sequencing.</p><p><strong>Results: </strong>ETV-treated patients had a longer time-to-relapse than that of TDF-treated patients (P = 0.0357). No drug-resistance related polymerase mutation was detected during relapses, except for a low percentage (1.4%) of rtM204I mutation in Patient 1. Two surface truncation mutations (sW216*; 40.9% and sW182*; 4.7%) detected before treatment in two TDF-treated patients (Patients 6 and 7, respectively) were overtaken by the wild types during subsequent drug-withdrawal-related relapses. The simultaneous presence of sG44E (T-cell epitope) and sE164G (B-cell epitope) mutations was associated with failure of HBV e antigen (HBeAg) seroclearance in ETV-treated patients.</p><p><strong>Conclusions: </strong>In conclusion, HBV genome continues to evolve during the courses of finite antiviral therapies. Pre-existing surface truncation mutations can be overtaken by the wild types after relapses. The sG44E/sE164G mutations are associated with failure of HBeAg seroclearance.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jgh.16791","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim: Hepatitis B virus (HBV) reactivation could develop after withdrawal following a finite course of nucleoside analog (NA) therapy, leading to virological and clinical relapses. The genetic heterogeneity in the HBV surface and polymerase genes during finite NA therapy has not been carefully studied.

Methods: Seven chronic HBV-infected patients experiencing relapses following entecavir (ETV; n = 5; Patients 1 to 5) or tenofovir disoproxil fumarate (TDF; n = 2; Patients 6 and 7) withdrawal were included. Sera obtained before treatment and at relapses were retrieved and submitted for DNA extraction and amplicon-specific deep sequencing.

Results: ETV-treated patients had a longer time-to-relapse than that of TDF-treated patients (P = 0.0357). No drug-resistance related polymerase mutation was detected during relapses, except for a low percentage (1.4%) of rtM204I mutation in Patient 1. Two surface truncation mutations (sW216*; 40.9% and sW182*; 4.7%) detected before treatment in two TDF-treated patients (Patients 6 and 7, respectively) were overtaken by the wild types during subsequent drug-withdrawal-related relapses. The simultaneous presence of sG44E (T-cell epitope) and sE164G (B-cell epitope) mutations was associated with failure of HBV e antigen (HBeAg) seroclearance in ETV-treated patients.

Conclusions: In conclusion, HBV genome continues to evolve during the courses of finite antiviral therapies. Pre-existing surface truncation mutations can be overtaken by the wild types after relapses. The sG44E/sE164G mutations are associated with failure of HBeAg seroclearance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受有限抗病毒治疗的患者体内乙型肝炎病毒聚合酶和表面基因的演变。
背景和目的:乙型肝炎病毒(HBV)可能在核苷类似物(NA)治疗的有限疗程后出现再激活,导致病毒学和临床复发。目前尚未仔细研究在有限的 NA 治疗过程中 HBV 表面基因和聚合酶基因的遗传异质性:方法:纳入了七名在恩替卡韦(ETV;n = 5;患者 1 至 5)或富马酸替诺福韦二吡呋酯(TDF;n = 2;患者 6 和 7)停药后复发的慢性 HBV 感染者。采集治疗前和复发时的血清,并进行DNA提取和扩增子特异性深度测序:结果:ETV治疗患者的复发时间长于TDF治疗患者(P = 0.0357)。在复发过程中,除了患者1的rtM204I突变比例较低(1.4%)外,未检测到与耐药性相关的聚合酶突变。在两名接受过 TDF 治疗的患者(患者 6 和 7,分别为 40.9% 和 4.7%)中,治疗前检测到两个表面截断突变(sW216*;40.9% 和 sW182*;4.7%),但在随后与停药相关的复发中被野生型取代。同时出现的sG44E(T细胞表位)和sE164G(B细胞表位)突变与ETV治疗患者的HBV e抗原(HBeAg)血清清除失败有关:总之,在有限的抗病毒治疗过程中,HBV 基因组仍在不断进化。复发后,原有的表面截断突变可被野生型取代。sG44E/sE164G突变与HBeAg血清清除失败有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
326
审稿时长
2.3 months
期刊介绍: Journal of Gastroenterology and Hepatology is produced 12 times per year and publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatology, gastroenterology and endoscopy. Papers cover the medical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas. All submitted papers are reviewed by at least two referees expert in the field of the submitted paper.
期刊最新文献
Post-colonoscopy upper gastrointestinal malignancies in positive immunochemical fecal occult blood test patients: An Australian data linkage study. Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy. New-onset diabetes mellitus and the risk of pancreatic cancer. Artificial intelligence-aided colonoscopic differential diagnosis between Crohn's disease and gastrointestinal tuberculosis. Long-term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti-tumor necrosis factor failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1